Chronic kidney disease (CKD) afflicts a large number of younger minority adults receiving medical care in settings that serve the uninsured and underinsured (settings collectively known as the healthcare safety net). Poor, minority adults with moderate to severe CKD are also two to four times more likely to progress to kidney failure than non-Hispanic whites. These are the findings from a study published online in the Clinical Journal of the American Society of Nephrology (CJASN).
The study indicates that targeted efforts to assess the burden and progression of CKD within the healthcare safety net are vital to improving the quality of care for this vulnerable population, and ultimately save lives.
Researchers at the University of Washington, the University of California San Francisco, and Stanford University examined data from 15,353 adults with non-dialysis dependent CKD stages 3-5. All were receiving regular ambulatory care in the Community Health Network of San Francisco and were followed for a period of 12-months to 9.4 years. The study authors measured the time it took for patients to progress from moderate to severe CKD to end-stage renal disease (ESRD) or death.
The vast majority of study participants were indigent, 40 percent were either uninsured or enrolled in Medicaid, and one-third spoke a primary language other than English - all vulnerable populations which have been underrepresented in prior studies of CKD.
In contrast to the general population and prior CKD studies in the United States, the study authors found CKD afflicted a large fraction of young adults (20-39 years old), most of whom were racial or ethnic minorities. Overall, African Americans, Hispanics, Asians and Pacific Islanders with CKD were at higher risk of developing ESRD, compared with non-Hispanic whites.
"Minorities in the United States are two to four times more likely than non-minorities to progress to ESRD," said Andy I. Choi, M.D., M.A.S., study co-author and assistant professor, Division of Nephrology, University of California, San Francisco. "That represents a significant disparity that warrants greater study about the causes, consequences and preventive measures appropriate for people in this demographic."
Because so little is known about CKD in the healthcare safety net, the authors call for additional research to assess what is needed to curb the progression of the disease, particularly among vulnerable populations. "More targeted research in these public healthcare and safety net settings is necessary to identify ways to slow the progression of the disease among the urban poor with CKD, thereby reducing disability and improving overall survival," said Yoshio N. Hall, M.D., study co-author and assistant professor of medicine, Kidney Research Institute, Division of Nephrology, University of Washington.
"Kidney disease is a growing problem in the United States, doubling in incidence over the last two decades. It's serious, and without proper diagnosis and treatment, kidney disease can lead to expensive treatments like transplantation or dialysis," said Sharon Anderson, M.D., FASN, president of the American Society of Nephrology. "Health care providers need to be especially vigilant screening patients who are most at-risk for developing kidney disease - minorities, seniors and those who have been diagnosed with diabetes, hypertension and/or cardiovascular disease."
The study is being published in conjunction with World Kidney Day, an international effort to raise awareness about the growing incidence of kidney disease and the need for increased funding for kidney disease research and education. Experts say more research can lead to treatments that could prevent or slow the disease's progression, save lives and reduce treatment costs. Currently, more than 26 million Americans, or one in nine adults, have chronic kidney disease. For more information about kidney disease and World Kidney Day, visit www.asn-online.org.
The article, entitled "Chronic Kidney Disease in the Urban Poor," will appear online at http://cjasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, the American Society of Nephrology (ASN) is the world's largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.